NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution

Stock Information for NeuBase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.